The best Bull and Bear pitches based on recency and number of recommendations.
Clovis isn't exactly flying under the radar ahead of the rociletinib Ad Comm on April 12. There's lots of commentary on the drug's prospects for approval, most of it negative. Of course, the shocking aspect of the whole situation was the blase way in… More
The financials on this one are fishier than a murder mystery dinner theater in Newfoundland. You can expect SG&A to go up in line with revenue a bit, but why does R&D increase with every revenue increase to wipe out all profits? I'm not saying… More
Read the most recent pitches from players about CLVS.
Recs
TMFjimhalley
(< 20)
Submitted: 5/12/2022 1:07:26 PM :
Start Price:
$1.74
NASDAQ:CLVS Score:
-113.81
It has a blockbuster drug, Rubraca, that has wide potential in oncology.
Recs
Capitalism
(71.89)
Submitted: 2/26/2018 1:20:40 PM :
Start Price:
$55.12
NASDAQ:CLVS Score:
-154.45
Richard Marzouka (SA) pick.
Recs
LifeScientist
(20.91)
Submitted: 2/17/2016 3:19:38 PM :
Start Price:
$19.78
NASDAQ:CLVS Score:
-222.16
technical near term bottom and nice upside two day trend; no insider selling of late since the drop last Nov. ( however no buying reported for 12 mos. ) top fools ZZlangerhaus and Seth15701 like it and former had a reasonable analysis .... Note, due to announce on Feb 25, so have to decide whether to hold it through earnings, but street's got a good negative expect of cash burn. Credit Suisse has picked it up with an analysis and an outperform since the Nov price drop.
Find the members with the highest scoring picks in CLVS.
anchak (99.73) Score: +387.02
The Score Leader is the player with the highest score across all their picks in CLVS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| KidJones | 28.28 | 12/3/2012 |
|
5Y | $15.59 | -99.81% | +202.39% | +302.20 | 0 Comment | |
| MFBurritoSquat | 66.88 | 11/30/2012 |
|
3M | $15.81 | -99.81% | +201.50% | +301.31 | 0 Comment | |
| IBDContrarian | 67.06 | 4/8/2013 |
|
5Y | $29.05 | -99.90% | +175.81% | +275.71 | 1 Comment | |
| kurzzz | 92.23 | 6/25/2013 |
|
5Y | $65.00 | -99.95% | +170.22% | +270.18 | 0 Comment | |
| ExpressRocks | 86.14 | 6/25/2013 |
|
5Y | $63.88 | -99.95% | +170.14% | +270.09 | 0 Comment | |
| bluebare | 28.67 | 6/14/2013 |
|
5Y | $69.38 | -99.96% | +162.75% | +262.70 | 0 Comment | |
| goldminingXpert | 27.56 | 5/13/2013 |
|
NS | $37.75 | -99.92% | +161.53% | +261.45 | 0 Comment | |
| kevian | 85.67 | 6/3/2013 |
|
1Y | $71.74 | -99.96% | +160.92% | +260.88 | 0 Comment | |
| navychop2 | 49.48 | 6/12/2014 |
|
1Y | $43.34 | -99.93% | +120.01% | +219.94 | 2 Comments | |
| GuruExp | 97.20 | 10/7/2014 |
|
5Y | $47.02 | -99.94% | +119.30% | +219.24 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
